Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
Veröffentlicht: 17.03.2026 um 19:23 Uhr, prnewswire.co.uk
View original content:https://www.prnewswire.co.uk/news-releases/asieris-cevira-approved-in-china-as-first-in-class-non-invasive-therapy-for-cervical-precancerous-lesions-302702287.html
en | boerse | 68729233 |
